
On the cover:
Positively determined to live: Kelli Nemecek, during her treatment for non-Hodgkin lymphoma.

“I was 26, and engaged to be married. Cancer was the last thing on my mind. But it happened. I made my first thought about dying my last thought about dying. My treatment is working and with the support of my family, friends and the Society, I remain positive — positive that there is a cure.”
This day in the life of Douglas Henry, pictured with son Jack, made possible by advances in cancer research.

“Tina and I were trying to have a baby when we learned I had leukemia. Once, it would have been a death sentence. Today, there’s hope. Knowing Jack was on the way during chemo gave me a powerful will to live. That and cancer research saved my life.”
It’s often said that converts make the most ardent supporters for a cause. If this is true, then our organization is particularly fortunate, for most of our supporters are converts. They are not born and raised with an intimate knowledge of blood cancers and the devastation they can cause. But in the blink of an eye, they learn. And from that moment on, they are converted.

So it was for Jim McKinnis. Out of the blue, in 2001, his 13-year old son, CJ, was diagnosed with acute lymphocytic leukemia (ALL). In that instant, Jim became relentless for his son’s cure, and he and his family spent that first year doing whatever it took to “get CJ well.” After that, Jim decided he had to keep on doing whatever he could to make cures a reality not only for his son, but for others as well.

Jim was the creative impetus behind many of the images you will see in this year’s annual report. As a creative director at the Tracy Locke Partnership, a Dallas-based advertising agency, Jim used his talent and the generosity of a host of people to produce the Society’s first integrated public awareness campaign. The photos of patients, family members, researchers, donors and volunteers featured throughout the report are part of the Society’s new campaign, “I’m Relentless for a Cure,” which debuted in public service television and radio ads in June 2003.

We remain grateful to our many supporters and ambassadors, and provide this report on our stewardship during the 2003 fiscal year in the hope that you will continue to be part of our relentless pursuit of cures for leukemia, lymphoma and myeloma.
More than 50 years ago, our family suffered the loss of a child to leukemia. Like so many families affected by blood cancers, we became, in a single moment, committed to finding cures for these devastating diseases.

The passion and dedication of like-minded people over the years have helped the Society achieve extraordinary advances in the treatment of leukemia, lymphoma and myeloma. Hundreds of thousands of patients and family members have benefited from Society information and support programs.

Advances in treatment are important milestones. But we must still strive for cures. That is why I continue to lend my name to the Society and endorse its ongoing efforts. Like my family and the millions of people in this country touched by cancer, the Society is indeed “relentless for a cure.” Their track record suggests that one day, soon we hope, cures will be a reality.

Barbara Bush
National Honorary Chair
The Leukemia & Lymphoma Society has invested nearly $360 million in medical research focused on hematologic malignancies since its founding in 1949. We currently underwrite the work of more than 425 cancer researchers throughout the world, through three major initiatives: the Specialized Center of Research (SCOR) program, the Translational Research Program, and the Career Development Program.
A myeloma researcher whose passion is life: Selina Chen-Kiang, Ph.D.

“Our work on the genetic basis of multiple myeloma, funded through the Society’s SCOR program,* is fired by the urgency to cure this cancer, which affects nearly 47,000 people in the U.S. today— with a five-year survival rate of only 32 percent. We’ve got to help find a cure!”

*Dr. Chen-Kiang’s SCOR team works at Weill Medical College of Cornell University, where she is Professor of Pathology and Professor of Microbiology and Immunology; Rockefeller University; and Memorial Sloan-Kettering Cancer Center, all in New York City.
Ten SCORs at Leading Institutions Around the World...

Specialized Center of Research (SCOR)

The SCOR program is a collaborative approach to finding cures, bringing together scientists within each center who are approaching a specific form of lymphoma, leukemia or myeloma from different vantage points. The goal is to generate synergy from these collaborations.

The Society’s objective — to fund nine SCORs between the beginning of fiscal year 2000 and the end of fiscal year 2003 — was ambitious. But we met it, with an additional SCOR, our 10th, approved to begin in fiscal year 2004. Combined funding for all 10 SCORs is $67 million spent or committed. The three new SCOR grants are:

✦ \textbf{Mechanisms of Treatment Responsiveness and Resistance in Myeloid Malignancies}

Team leader Scott Lowe, Ph.D., Director of Cold Spring Harbor Laboratory in New York, is collaborating with researchers at the University of Chicago, the University of Minnesota and the University of California, San Francisco. The team is attacking the problem of resistance to chemotherapy among patients with acute myelogenous leukemia (AML), a cancer with a very low cure rate.

✦ \textbf{Cellular Immunotherapy of Lymphoma}

Team leader Helen Heslop, M.D., Director of the Baylor College of Medicine Center for Cell and Gene Therapy, in Texas, and her team, are studying the anti-tumor effects of a class of T cells known as cytotoxic T lymphocytes (CTLs), which provide effective therapy for some forms of lymphoma by triggering the immune system to attack the cancer cells directly.

✦ \textbf{Molecular Targets in Lymphoma}

Riccardo Dalla-Favera, M.D., Director of the Columbia University Institute for Cancer Genetics, and his team are working in collaboration with Memorial Sloan-Kettering Cancer Center (both in New York City), to study the origin of B cell-derived non-Hodgkin lymphoma, with a focus on follicular lymphoma, the most common type. They will identify genetic lesions associated with this cancer and determine how these lesions contribute to cancer growth in mouse models and in vitro studies. The findings of this study should lead to new diagnostic methods for correcting or deactivating the defects caused by the lesions.

Dr. Donald Small’s Society-funded translational research* leads to a breakthrough in the treatment of acute myelogenous leukemia (AML).

\textit{“We hoped to use the FLT3 gene we cloned to expand blood stem cells. But once mutations of it were found in leukemia, our team worked hard to identify agents that would inhibit the mutated gene and kill the AML cells. Hopefully, we’ve turned the tables on this cancer so that the very abnormality that makes it so deadly could be what also makes it curable.”}

* Donald Small, M.D., Ph.D., and his team are at Johns Hopkins University, in Baltimore, MD. Dr. Small is funded by a generous gift to the Society from the Douglas Kroll Research Program.
Attracting Talented Investigators to Blood Cancer Research

The Career Development Program funds investigators at different points in their careers: as Scholars, Clinical Scholars, Fellows or Special Fellows. It gives young scientists the opportunity to work in the field of blood cancer research, helping the field grow talent for the long term. The program supports fundamental research in genetics, molecular and cell biology, molecular pharmacology, molecular virology and immunology. In 2003, the program met its goal of providing new grants to 66 researchers, the best and brightest from a pool of 417 applicants.

Translational Research

The Translational Research Program (TRP) funds research projects that demonstrate high promise for accelerating the rate at which scientific knowledge becomes better therapies for patients. Translational research comprises projects that are in or approaching clinical trials. Since 1995, the program has awarded nearly $100 million to these projects.

During 2003, TRP investigators made major strides in our understanding of the causes of certain blood cancers and how to treat them with therapies that kill cancer cells with minimal effects on normal cells. Two highlights follow:

✦ Richard J. Ford, M.D., Ph.D., of the University of Texas M.D. Anderson Cancer Center, in Houston, showed that a new cancer drug, Velcade™ (bortezomib), destroys mantle cell lymphocytes by blocking a key factor responsible for regulating cell growth. Velcade was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma, and now offers hope to patients with mantle cell lymphoma, a rare and often fatal form of blood cancer.

Dr. Ford’s study also shows that Velcade works on the fundamental regulators of cell growth and has the potential to treat cancers of the breast, colon and prostate.

✦ In another Translational Research study funded by the Society, Gary Gilliland*, Ph.D, M.D., of Harvard Medical School and Brigham and Women’s Hospital in Boston, MA, showed that Gleevec® is effective in the treatment of hypereosinophilic syndrome, a rare blood cancer.

Gleevec, a targeted therapy in pill form, is a drug approved by the FDA for the treatment of chronic myelogenous leukemia (CML), and has also shown promise in the treatment of certain stomach tumors and chronic myelomonocytic leukemia (CMML). Gleevec was pioneered by Brian Druker*, M.D., in another Society-funded project.

* Dr. Gilliland is a former Stephen Birnbaum Scholar
* The Specialized Center of Research grant of Dr. Druker is funded in part by a generous gift to the Society from the Bertelsen Family.

Five-Year Survival Rates

\[\text{Survival rate is an important indicator of progress in achieving our research goals.}\]
Diagnosed with lymphoma not once, but twice, Delois Smith became a human battleground.

“Here come the troops! Receiving chemotherapy, I pictured it as soldiers, killing the cancer cells. I had two months to live . . . unless the treatment worked. Friends from the Society held my hand as two months became a year. Then, it was over. I was cancer free.”
IMPROVING QUALITY OF LIFE OF PATIENTS

The Society's Information Resource Center (IRC), Web site and 60 community-based chapters are a critical resource for patients, their families and friends. Through them, the Society logged 451,198 interactions with people across the country in fiscal year 2003, more than doubling 2002 figures and exceeding its goal.
The Society’s Web Site

Keeping Patients Connected

The Society’s Web site, www.LLS.org, provides the who, what, when, where and how for patients and their families, healthcare professionals and other friends of the Society, and serves as an online community. Visits to our patient services pages in fiscal year 2003 were a record 321,000.

The Society also hosted 14 new educational programs in 2003. These Webcasts and teleconferences are archived on our site so patients and others can continue to access them after the live events. New educational programs this year covered the spectrum from specific blood cancer issues to survivorship issues for all cancer patients. Examples include:

- A series of CMLLinks teleconferences for patients with chronic myelogenous leukemia (CML), including *New Horizons in the Treatment of CML*, a live Webcast in which Gleevec pioneer Brian Druker, M.D., discussed the impact of this new therapy, along with two patients who shared their experiences. This educational program was supported by a generous grant from Novartis Pharmaceuticals.

  http://www.LLS.org/cmlteleconferences

- *Developments in Myeloma Management*, a telephone education workshop that covered treatment options, clinical trials and quality of life issues for myeloma patients.

  http://www.LLS.org/myelomaeducation

- *Lymphoma and the Older Patient*, a telephone education workshop that addressed the specific concerns and issues of elderly patients, supported by GlaxoSmithKline.

  http://www.LLS.org/lymphomaeducation

- *Cancer: Keys to Survivorship*, the third in a series of Webcasts that arm cancer survivors with the information and skills necessary to advocate for themselves while coping with a new cancer diagnosis. Over the past seven years, this program has been supported by an educational grant from Ortho Biotech Products L.P.

  http://www.LLS.org/survivorshipeducation
Meet Zach Papin, a 7-year old leukemia survivor who’s a winner — with the medals to prove it.

“At 4 1/2, Zach the whirlwind suddenly stopped moving,” says his dad, Jim. “Hearing he had acute lymphocytic leukemia (ALL) felt like being run over by a train. But Zach the wrestler wouldn’t stay down, and thanks to advances made possible by research, he’s now back to normal. Once, kids with ALL had ‘90 days,’ but because of research, my son has an 85 percent chance of surviving.”
Lorraine Jacobs is bent on destruction.

“My husband, Jim, was a fighter. That’s what got him into the Handball Hall of Fame and made him so successful in the world of boxing. After his death from chronic lymphocytic leukemia (CLL), I became a fighter in his memory. My fight: to destroy the cancer that took him down.”

Grassroots Support and Information

Our 60 chapters across the United States provide a human touch to outreach efforts, serving patients with support and information and connecting them with other patients and families who share their concerns. Each chapter has a dedicated patient services professional to serve and support local patients and families. More than 400 Family Support Groups were active in chapters during 2003. Educational programs such as Meet the Expert on non-Hodgkin Lymphoma, sponsored by Genentech/IDEC Pharmaceuticals, give patients, friends and family access to disease-specific specialists right in their own communities.

The physician who diagnosed Robert Frank with CLL was not optimistic. A new doctor and a new protocol brought remission, but no one expected it to last — except Robert Frank.

“When the new drug got me into solid remission, a bone marrow harvest was performed so I could have a bone marrow transplant when I came out of remission. I’ve never needed the transplant, and my doctor calls me his ‘miracle man.’”

Contact our IRC at 800.955.4572 or visit our Web site at www.LLS.org.
In fiscal year 2003:

<table>
<thead>
<tr>
<th>Count</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>321,000</td>
<td>unique visits to disease information Web pages</td>
</tr>
<tr>
<td>46,446</td>
<td>Information Resource Center responses to patients, caregivers and healthcare professionals</td>
</tr>
<tr>
<td>30,000</td>
<td>participants in four Webcasts</td>
</tr>
<tr>
<td>10,668</td>
<td>participants in 10 nationwide teleconferences</td>
</tr>
<tr>
<td>20,823</td>
<td>participants in education programs</td>
</tr>
<tr>
<td>11,000</td>
<td>patients and family members in Family Support Groups and First Connection</td>
</tr>
<tr>
<td>11,261</td>
<td>recipients of patient financial aid</td>
</tr>
</tbody>
</table>
The importance of making our voices heard in Congress cannot be understated. To that end, the Society more than doubled our Advocates Network in 2003. With more than 15,000 registered advocates now working at the grassroots level and in Washington, DC, we aim to keep funding for blood cancer research, and attention to issues of importance to patients, front and center among policy makers.

In March, 130 advocates from 34 states visited Capitol Hill, logging 160 visits with senators and representatives in a single day. And Congress listened, with $5 million now slated for the U.S. Department of Defense for research into chronic myelogenous leukemia (CML) and another $5 million allocated to the Centers for Disease Control and Prevention for blood cancer education.

Society advocates are also making progress at the state level. An outstanding example is new legislation in Illinois that provides for a state income tax check-off box to fund programs for the treatment and education of patients with leukemia, lymphoma and myeloma.
A bone marrow transplant saved Clare Chaney’s life. Now she lives to help others survive cancer.

“Real life’s an adventure, not a fairy tale that ends ‘happily ever after.’ We have to fight and we need all the help we can get. I try and use my ‘saved’ life to encourage others and fight for government funding to help arm cancer patients so they can win their battles.”
Her mom ran out of treatment options and went into hospice care. But Mary Beth Hirsch was just getting started.

“My mom had an aggressive form of lymphoma. After months of treatment and teetering on the brink of death, she resigned herself to the cancer. But I wanted to make a difference. I signed up for a TNT triathlon and raised funds for research. Miraculously, as I got stronger, so did mom. Soon she no longer needed hospice care. Mom attended the triathlon with me and we crossed the finish line hand-in-hand. We both won.”
Cures will come from research. Research requires funding. In pursuit of our mission, the Society set ambitious revenue goals knowing that difficult economic conditions don’t change the fact that more people are fighting blood cancers this year than last year. More than 670,000 men, women and children are battling leukemia, lymphoma and myeloma in 2003. Someone new is diagnosed every five minutes. Every nine minutes, someone loses the fight.

The Society ended fiscal year 2003 with results that met or exceeded targets in most areas: Net revenue of $164 million was 5 percent better than our objective and $12.5 million higher than last year.
Light The Night®
Walk

A Rising Star

The Light The Night Walk continued its phenomenal growth track in fiscal year 2003, with net revenue increasing 34 percent over the prior year. The event was held at hundreds of locations around the country in fall 2002. One-hundred forty thousand participants walked in the event, and the number of corporate and family teams increased by 30 percent, to more than 10,000.

Team In Training®
Fitness and Fundraising for Cures

Our Team In Training (TNT) program, now in its 15th year, is truly the jewel in the crown. In 2003, Team In Training officially added Nike to its list of presenting sponsors – a partnership that promises to serve well the interests of both organizations. TNT’s triathlon training proved to be a strong addition to the program, with net revenue growth of $2.8 million this year over last and nearly 800 participants. The year 2003 saw many TNT “firsts.” The first individual to raise $1 million in the Society’s history was Bruce Cleland, the pioneer who started TNT in 1988. The First Annual TNT Alumni Reunion, staged at the Suzuki® Rock ‘n’ Roll Marathon®, raised $1.9 million for the Society. And a new event for TNT, the Rock ‘n’ Roll Half Marathon in Virginia Beach, attracted 800 TNT participants, who raised $2 million in revenue.

Team In Training athlete/fundraiser Carmello Elie honors his mother, lost to lymphoma after a 10-year battle.

“My running had no purpose until my mother died. When I discovered I could train to run the New York City Marathon and do something for cancer patients in mom’s memory, I went for it. I’ve done marathons, a triathlon, and I’m a TNT mentor. Whenever I hit an obstacle, I remember my mom’s resilience, and it gives me the focus and determination to keep going.”
Samantha Palka learned “The Power of One” through the Society’s School & Youth Programs.

“When our school started collecting money to help people with cancer, I wasn’t sure how I could make a difference. But then I found out that one kid at a time, one school at a time, students around the country raised over $10 million last year. That made me feel like I had the power to do a lot!”

School & Youth℠ Programs

The Power of One

In 2003, 6 million school children in more than 12,000 schools throughout the country participated in the Society’s School & Youth Programs. These children raised $10.3 million to fund cancer research and patient services. Collecting their own change and asking family members and friends to contribute, they discovered that they have the power to make a difference in the lives of others.

Donor Development

With Gratitude

Thanks to the generosity of our donors in 2003, the Society made major advances toward fulfilling our mission. We continued to grow our Legacy Circle, which now has 380 members and an estimated value of $15 million.

This year, the Society also received the largest individual gift in our history: $6.2 million from a family in New York City. This gift was earmarked to help ensure the continuation of our leading-edge research programs. Donors may elect to restrict their gifts to a program based on a specific project or disease type, or to one of 425 Society-sponsored researchers at more than 120 distinguished medical research institutions in the United States, Canada and abroad. Alternatively, donors may support one of our patient services programs, either nationally or on the local level.
The Specialized Center of Research grant of Dr. Adams is funded in part by a generous gift to the Society from Eli Lilly and Company.

The Specialized Center of Research grant of Dr. Bernstein is funded in part by a generous gift to the Society from The Stephen Birnbaum Foundation.

The Specialized Center of Research grant of Dr. Druker is funded in part by a generous gift from St. Valentine's Day Luncheon & Style Show.

The Specialized Center of Research grant of Dr. Daley is funded in part by a generous gift to the Society from The Stephen Birnbaum Foundation.

The Specialized Center of Research grant of Dr. Koleske is funded in part by a generous gift to the Society from Valence Aspinwall & The Reichman Memorial/Altschul Darcy and the Darcy Valentine Research Fund.

The Specialized Center of Research grant of Dr. Nucifora is funded in part by a generous gift to the Society from The Gil Cohen Leukemia Fund.

The Specialized Center of Research grant of Dr. Teitell is funded in part by a generous gift to the Society from The Stephen Birnbaum Foundation.

Research Grants

Specialized Center of Research

Jerry Adams, PhD • 2002
Walter & Eliza Hall Institute of Medical Research

Irwin Bernstein, MD • 2003
Fred Hutchinson Cancer Research Center

Selina Chen-Xiang, PhD • 2001
Weill Medical College of Cornell University

Riccardo Dalla-Favera, MD • 2004
Columbia University

Brian Druker, MD • 2001
Oregon Health & Science University

James Griffin, MD • 2001
Dana-Farber Cancer Institute

Helen Heslop, MD • 2004
Baylor College of Medicine

Carl June, MD • 2002
University of Pennsylvania School of Medicine

Scott Lowe, PhD • 2004
Cold Spring Harbor Laboratory

Stephen Nimer, MD • 2002
Memorial Sloan-Kettering Cancer Center

Career Development Program

Peter Adams, PhD • 2004
Fox Chase Cancer Center

Francisco Asturias, PhD • 2002
 Scripps Research Institute

Donald Ayer, PhD • 1999
University of Utah School of Medicine

Ravi Basavappa, PhD • 2000
University of Rochester

Katherine Borden, PhD • 2001
Mount Sinai School of Medicine

James Bowie, PhD • 2002
University of California at Los Angeles

Randy Brkutkiewicz, PhD • 2004
Indiana University School of Medicine

Stephen Buratowski, PhD • 2000
Harvard Medical School

Anthony Capobianco, PhD • 2002
University of Cincinnati College of Medicine

J. Don Chen, PhD • 2001
University of Medicine and Dentistry of New Jersey

Zhijian Chen, PhD • 2005
University of Texas Southwestern Medical Center at Dallas

Genhong Cheng, PhD • 2001
University of California at Los Angeles

K.M. Coggeshall, PhD • 1999
Oklahoma Medical Research Foundation

Pamela Correll, PhD • 2005
Pennsylvania State University

Patricia Cortes, PhD • 2002
Mount Sinai School of Medicine

Chris Counter, PhD • 2003
Duke University Medical Center

Gay Crooks, MD • 2000
Children’s Hospital of Los Angeles

George Daley, MD, PhD • 2000
Children’s Hospital of Boston

James DeGregori, PhD • 2001
University of Colorado Health Sciences Center

Wei Du, PhD • 2004
University of Chicago

Michael Eck, MD, PhD • 2003
Dana-Farber Cancer Institute

Laurence Eisenhoffer, PhD, VMD • 2000
Thomas Jefferson University

Xin-Hua Feng, PhD • 2004
Baylor College of Medicine

Alan Friedman, MD • 1999
Johns Hopkins University School of Medicine

Margaret Goodell, PhD • 2002
Baylor College of Medicine

Jonathan Graff, MD, PhD • 2002
University of Texas Southwestern Medical Center at Dallas

Wei Gu, PhD • 2002
Columbia University

Anthony Imbalzano, PhD • 2000
University of Massachusetts Medical School

Theodore Jardetzky, PhD • 2002
Northwestern University School of Medicine

Jin Jiang, PhD • 2004
University of Texas Southwestern Medical Center at Dallas

Dong-Yan Jin, MD, PhD • 2002
University of Hong Kong

Craig Jordan, PhD • 2004
University of Rochester

Jae Jung, PhD • 2001
Harvard Medical School

Michelle Kellihier, PhD • 2004
University of Massachusetts Medical School

William Kerr, PhD • 2003
H. Lee Mofitt Cancer Research Center

Nigel Killeen, PhD • 2001
University of California at San Francisco

Michael Koelle, PhD • 2000
Yale University School of Medicine

Anthony Koleske, PhD • 2003
Yale University

Sally Kornbluth, PhD • 1999
Duke University Medical Center

Kerry Kornfeld, MD, PhD • 2002
Washington University School of Medicine

Stephen Kron, MD, PhD • 2003
University of Chicago

David Lambright, PhD • 1999
University of Massachusetts Medical School

Daniel Lew, PhD • 2001
Duke University Medical Center

Hsiou-Chi Liu, PhD • 2001
Weill Medical College of Cornell University

Fenyong Liu, PhD • 2002
University of California at Berkeley

Clifford Lowell, MD, PhD • 2002
University of California at San Francisco

Kun Ping Lu, MD, PhD • 1999
Beth Israel Deaconess Medical Center

Andreas Matouschek, PhD • 2003
Northwestern University School of Medicine

Dunesh Moazed, PhD • 2004
Harvard Medical School

Giuseppina Nucifora, PhD • 1999
University of Illinois at Chicago

Matthew O’Connell, PhD • 2001
Mount Sinai School of Medicine

Warren Pear, MD, PhD • 1999
University of Pennsylvania School of Medicine

David Pellman, MD • 2001
Dana-Farber Cancer Institute

Christoph Plass, PhD • 2003
Ohio State University Comprehensive Cancer Center

David Rawlings, MD • 2000
University of Washington School of Medicine

Rubaiyu Ren, MD, PhD • 1999
Brandeis University

Erle Robertson, PhD • 2000
University of Pennsylvania School of Medicine

Moshe Sadoskog, MD, PhD • 2000
Albert Einstein College of Medicine of Yeshiva University

Kathleen Sakamoto, MD • 1999
University of California at Los Angeles

Guy Sauvageau, MD, PhD • 2003
Clinical Research Institute of Montreal

Edward Scott, PhD • 1999
University of Florida Shands Cancer Center

David Selim, MD, PhD • 2001
Boston Medical Center

Ali Shilahtifard, PhD • 2002
Saint Louis University School of Medicine

Ramesh Shivdasani, MD, PhD • 2001
Dana-Farber Cancer Institute

Gerald Siu, MD, PhD • 2001
Columbia University

Tomasz Skorski, MD, PhD • 2001
Temple University

Charles Suri, PhD • 2000
Scripps Research Institute

Guilermo Tacciotti, PhD • 1999
Boston University School of Medicine

Reshma Taneja, PhD • 2003
Mount Sinai School of Medicine

William Tansey, PhD • 2002
Cold Spring Harbor Laboratory

Michael Teitell, MD • 2004
University of California at Los Angeles

Dimitris Thanos, PhD • 2001
Biomedical Sciences Research Center

Michael Thirman, MD • 2003
University of Chicago Department of Medicine

Sheila Thomas, PhD • 2000
Beth Israel Deaconess Medical Center

David Toczyski, PhD • 2004
University of California at San Francisco Comprehensive Cancer Center

Toshio Tsujiyama, DVM • 2003
Fred Hutchinson Cancer Research Center

Jessica Tyler, PhD • 2004
University of Colorado Health Sciences Center

Richard Van Etten, MD, PhD • 1999
CWR Institute of Biomedical Research, Inc.

David Van Vactor, PhD • 2001
Harvard Medical School

David Vaux, PhD • 2000
Walter & Eliza Hall Institute of Medical Research

2 The Specialized Center of Research Grant Program is supported in part by a generous contribution from General Motors.

3 The Specialized Center of Research grant of Dr. Adams is funded in part by a generous gift to the Society from Eli Lilly and Company.

4 The Specialized Center of Research grant of Dr. Drucker is funded in part by a generous gift to the Society from Charles and Shirley Wexner Family.

5 The Specialized Center of Research grant of Dr. Drucker is funded in part by a generous gift to the Society from The Stephen Birnbaum Foundation.

6 Dr. Crooks is funded in part by a generous gift to the Society from The Stephen Birnbaum Foundation.

7 Dr. Crooks is funded in part by a generous gift to the Society from The Stephen Birnbaum Foundation.

8 Dr. Daley is funded in part by a generous gift to the Society from The Stephen Birnbaum Foundation.
Mary Laughlin, MD • 1999
Case Western Reserve University

Jane Liesveld, MD • 1999
University of Rochester Medical Center

Dana Matthews, MD • 2000
Fred Hutchinson Cancer Research Center

Nikhil Munshi, MD • 1999
Dana-Farber Cancer Institute

Owen O’Connor, MD, PhD • 2003
Memorial Sloan-Kettering Cancer Center

Aaron Rapoport, MD • 2002
University of Maryland

Robert Soiffer, MD • 2000
Dana-Farber Cancer Institute

Jeffrey Tauh, MD • 2003
Wayne State University

Children's Hospital of Michigan

Edmund Waller, MD, PhD • 1999
Emory University

Christopher Walsh, MD, PhD • 2001
Mount Sinai School of Medicine

Joseph Wiemels, PhD • 2004
University of California at San Francisco

Career Development Program
• Scholar in Clinical Research

Maurizio Bendandi, MD, PhD • 2002
Clinica Universitaria, University of Navarra

Ravi Bhatia, MD • 2003
City of Hope National Medical Center

Smita Bhatia, MD MPH • 2002
City of Hope National Medical Center

Robert Brodsky, MD • 2001
Johns Hopkins Oncology Center

Richard Burt, MD • 1999
Northwestern University School of Medicine

John Byrd, MD • 2002
Ohio State University

Comprehensive Cancer Center

Martin Carroll, MD • 2004
University of Pennsylvania School of Medicine

Jorge Cortes, MD • 2001
University of Texas

MD Anderson Cancer Center

Glenn Dranoff, MD • 2001
Dana-Farber Cancer Institute

Ephraim Fuchs, MD • 2004
Johns Hopkins University School of Medicine

Steven Gore, MD • 1999
Johns Hopkins University School of Medicine

Omer Koc, MD • 2002
Case Western Reserve University

Fernando Casares, PhD • 2001
Universidade do Porto

Po Chen, PhD • 2001
University of Texas

Southwestern Medical Center at Dallas

Aiyang Cheng, PhD • 2004
Yale University School of Medicine

Chung Chung, PhD • 2001
Vanderbilt University Medical Center

Hilary Coller, PhD • 2003
Fred Hutchinson Cancer Research Center

Laurent Coscoy, PhD • 2002
University of California at Berkeley

Xu-Ming Dai, MD, PhD • 2003
Albert Einstein College of Medicine

Nika Danial, PhD • 2004
Dana-Farber Cancer Institute

Beatrice Darmont, PhD • 2000
University of Oregon

Randall Davis, MD • 2004
University of Alabama at Birmingham

Roberto De Guzman, PhD • 2005
Scripps Research Institute

Miguel del Pozo, MD, PhD • 2002
Scripps Research Institute

Laxminarayana Devireddy, PhD • 2005
University of Massachusetts Medical School

Jixiang Ding, PhD • 2002
University of Louisville

Mensur Dlakic, PhD • 2001
University of Michigan

Calin Dumitru, MD, PhD • 2002
Thomas Jefferson University

Kimmel Cancer Center

Patricia Ernst, PhD • 2002
Dana-Farber Cancer Institute

Beate Heissig, PhD • 2004
Juntendo University School of Medicine

Gabriela Hernandez-Hoyos, PhD • 2002
California Institute of Technology

Patrick Humbert, PhD • 2002
Peter MacCallum Cancer Institute

Lena Hwang, PhD • 2003
University of California at Berkeley

Masato Ieda, PhD • 2002
Northwestern University School of Medicine

Shin-ichiro Imai, MD, PhD • 2002
Washington University School of Medicine

Andreas Ivesa, PhD • 2002
Princeton University

Julie Jameson, PhD • 2004
Scripps Research Institute

Janusz Kabarowski, PhD • 2003
University of Alabama at Birmingham

Chang Kim, PhD • 2003
Purdue University

Alexei Kisselev, PhD • 2002
Harvard Medical School

Paul Knoepfler, PhD • 2003
Fred Hutchinson Cancer Research Center

21 Dr. Ernst is funded by a generous gift to the Society from St. Valentine’s Day Luncheon & Style Show.

22 Dr. Ivessa is funded in part by a generous gift to the Society from Parents Against Leukemia.

23 Dr. Hwang is funded by a generous gift to the Society from The Newman Foundation.

24 Dr. Kornfeld is funded by a generous gift to the Society from Ed Heitz Memorial Research Fund.

25 Dr. Kisselev is funded in part by a generous gift to the Society from The Karyn Glick Special Fellowship.

26 Dr. Knoepfler is funded by a generous gift to the Society from the Wayne & Gladys Valley Foundation.

27 Dr. Coscoy is funded by a generous gift to the Society from Delina Sanfordllips in memory of Joe Sanfordllips.

28 Dr. Dworin is funded in part by a generous gift to the Society from the Remillard Family Foundation, Inc.

29 Dr. Ernst is funded by a generous gift to the Society from The Helen Brach Foundation.

30 Dr. Nucifora is funded in part by a generous gift to the Society from The Newman Foundation.

31 Dr. Shilatifard is funded by a generous gift to the Society from Edward Lifshitz Memorial Research Fund.

32 Dr. Devireddy is funded in part by a generous gift to the Society by the Helen Brach Foundation.

33 Dr. Coscoy is funded in part by a generous gift to the Society from The Newman Foundation.

34 Dr. Nucifora is funded in part by a generous gift to the Society by the Helen Brach Foundation.
Research Grants

continued

Geeta Narlikar, PhD • 2002
University of California at San Francisco
Mikhail Nikiforov, PhD • 2003
Princeton University
Laura Pasqualucci, MD • 2003
Columbia University
Yuri Pekarsky, PhD • 2001
Thomas Jefferson University
Gabriela Perez-Alvarado, PhD • 2001
Scripps Research Institute
Joel Pomerantz, PhD • 2001
California Institute of Technology
Toni Portis, PhD • 2003
Northwestern University School of Medicine
Pascal Preker, PhD • 2001
University of California at San Francisco
Vivienne Rebel, MD, PhD • 2002
Dana-Farber Cancer Institute
Yosef Refaeli, PhD • 2003
University of California at San Francisco
Karim Reif, PhD • 2002 24
University of California at San Francisco
Gary Reuther, PhD • 2002
University of North Carolina at Chapel Hill
Nicholas Rhind, PhD • 2000
University of Massachusetts Medical School
Inez Rogatsk, PhD • 2003
University of California at San Francisco
Joan Roig Amoros, PhD • 2003
Massachusetts General Hospital
Akhide Ryo, MD, PhD • 2003
Yokohama City University
Shireen Saleque, PhD • 2004
Children’s Hospital of Boston
Brian Schaefer, PhD • 2001
National Jewish Medical and Research Center
Clemens Schmitt, MD • 2001
Max Delbruck Center for Molecular Medicine
Brenda Schulman, PhD • 2001
St. Jude Children’s Research Hospital
Anthony Schwacha, PhD • 2002
University of Pittsburgh
Jill Schweitzer, PhD • 2004
University of Notre Dame
Clare Scott, MD, PhD • 2004
Cold Spring Harbor Laboratory
JoAnn Sekiguchi, PhD • 2002 25
University of Michigan
Julia Serano, PhD • 2001
University of California at Berkeley
Hirono Sessaki, PhD • 2002
Johns Hopkins University School of Medicine
David Sherwood, PhD • 2003
California Institute of Technology
Keichi Shibahara, MD, PhD • 2001
Japan Science and Technology Corporation
Protal Shrikant, PhD • 2001
Roswell Park Cancer Institute
Jeffrey Singer, PhD • 2002
Brown University
Chi Wai So, PhD • 2003
Stanford University
Srinivasa Srinivasula, PhD • 2001
Thomas Jefferson University
David Steger, PhD • 2001
University of California at San Francisco
Bodo Stern, PhD • 2002
Harvard Medical School
Valery Sudakin, DSC • 2003
Fox Chase Cancer Center
Susanne Szabo, PhD • 2001
Harvard School of Public Health
Takashi Tanaka, PhD • 2001
Harvard School of Public Health
Scott Tihedt, PhD • 2004
Washington University School of Medicine
Alexei Touzchkin, PhD • 2002
Scripps Research Institute
Benjamin Turk, PhD • 2003
Beth Israel Deaconess Medical Center
Fred van Leeuwen, PhD • 2004
Fred Hutchinson Cancer Research Center
Hisne Martien Van Santen, PhD • 2001
Joslin Diabetes Center
Jose Villadangos, PhD • 2001
Walter & Eliza Hall Institute of Medical Research
Marc Vodicka, PhD • 2001
Fred Hutchinson Cancer Research Center
Gelin Wang, PhD • 2004
University of Texas Southwestern Medical Center at Dallas
Yanchang Wang, PhD • 2002
Florida State University College of Medicine
Amy Weinmann, PhD • 2004
University of Wisconsin at Madison
Eric Weiss, PhD • 2002
Northwestern University School of Medicine
Ting-Ting Wu, PhD • 2002
University of California at Los Angeles
Ping Xie, PhD • 2005
University of Iowa
Jinsong Zhang, PhD • 2004
Rockefeller University
Wei-Xing Zong, PhD • 2004
University of Pennsylvania School of Medicine
Emmanuel Zorn, PhD • 2002
Dana-Farber Cancer Institute

Career Development Program
A Fellow
Joan Adamo, PhD • 2003
Princeton University
Dikran Aivazian, PhD • 2005 26
Stanford University School of Medicine
Bjoern Albrecht, PhD • 2005
New York University School of Medicine
Robert Allen, PhD • 2002
Emory University
Jennifer Antonchuk, PhD • 2004
Walter & Eliza Hall Institute of Medical Research
Toshiyuki Araki, PhD • 2003
Beth Israel Deaconess Medical Center
Nagi Ayd, PhD • 2001
Harvard Medical School
Beth Baber-Furnari, PhD • 2002
Salk Institute for Biological Studies
Vladimir Badovinac, PhD • 2002
University of Iowa
Peggy Baudouin-Cornu, PhD
French DEA • 2004
Mount Sinai Hospital
John Bellizzi, PhD • 2002
Harvard Medical School
William Blalock, PhD • 2002
University of Florida
Michelle Booden, PhD • 2002
University of North Carolina at Chapel Hill
Douglas Braaten, PhD • 2003
Washington University School of Medicine
Benjamin Braun, MD, PhD • 2004
University of California at San Francisco
Scott Briggs, PhD • 2002
Purdue University

24 Dr. Rief is funded in part by a generous gift to the Society from the Friends of Sue Rinsky.
25 Dr. Aivazian is funded in part by a generous gift to the Society from the Friends of Sue Rinsky.
Dr. Keating is funded by a generous gift to the Society for the Study of Molecular Immunology.

Dr. Sondermann is funded by a generous gift

Dr. Shah is funded by a generous gift to the Society from Delora Sanfilippo in memory of her late husband.

Dr. Speck is funded in part by a grant from the New York City Council on the Arts.

Dr. Fisher is funded by a generous gift to the Society from The Charlotte Meyers Research Fund.

Dr. Keating is funded by a generous gift to the Society from Delora Sanfilippo in memory of her late husband.

Dr. Keating is funded by a generous gift to the Society from Delora Sanfilippo in memory of her late husband.

Dr. Sondermann is funded by a generous gift

Dr. Speck is funded in part by a grant from the New York State Department of Health on behalf of Senator Charles Fuschillo.
Research Grants

continued

Dr. Bhatia is funded by a generous gift to the Society from The Chuck Griffin Memorial Research Program.

Dong Yu, PhD • 2001
Princeton University

Katherine Zahradka, PhD • 2002
Mount Sinai School of Medicine

Chengcheng Zhang, PhD • 2002
Whitehead Institute for Biomedical Research

Jing Zhang, PhD • 2004
Whitehead Institute for Biomedical Research

Jingsong Zhang, PhD • 2001
Bucknell University

Xiaowu Zhang, PhD • 2003
Whitehead Institute for Biomedical Research

Fangyi Zhao, PhD • 2003
University of Minnesota Cancer Center

Translational Research Program

Vahid Afsar-Kharghan, MD • 2003
Baylor College of Medicine

Ricardo Aguilar, MD, PhD • 2002
Dana-Farber Cancer Institute

Denis Alexander, PhD • 2003
Babraham Institute

Stephen Ansell, MD, PhD • 2004
Mayo Clinic and Foundation

Scott Armstrong, MD, PhD • 2004
Dana-Farber Cancer Institute

David Avigan, MD • 2002
Beth Israel Deaconess Medical Center

Maria Baer, MD • 2005
Roswell Park Cancer Institute

David Bahler, MD, PhD • 1999
University of Utah School of Medicine

Albert Baldwin, PhD • 1998
University of North Carolina at Chapel Hill

Edward Ball, MD • 1997
University of California at San Diego

Deborah Banker, PhD • 2002
Fred Hutchinson Cancer Research Center

Peter Leif Bergsagel, MD • 1999
Well Medical College of Cornell University

Steven Bernstein, MD • 2004
University of Rochester

Ravi Bhatia, MD • 2000
City of Hope National Medical Center

Ravi Bhatia, MD • 2003
City of Hope National Medical Center

Smita Bhatia, MD, MPH • 2002
City of Hope National Medical Center

Ivan Borrello, MD • 2001
Johns Hopkins University School of Medicine

H. Scott Boswell, MD • 2002
Indiana University

Michael Boyer, MD • 2000
Children’s Hospital Medical Center

John Bushweller, PhD • 2002
University of Virginia

Martin Carroll, MD • 2004
University of Pennsylvania School of Medicine

William Carroll, MD • 2000
Mount Sinai School of Medicine

Robert Castleberry, MD • 2002
University of Alabama at Birmingham

Ethel Ceserman, MD, PhD • 2002
Weill Medical College of Cornell University

Linziao Chen, PhD • 2002
Johns Hopkins University School of Medicine

Curt Clevin, MD • 2001
Johns Hopkins University School of Medicine

Bayard Clarkson, MD • 2004
Sloan-Kettering Institute for Cancer Research

David Claxton, MD • 2000
Pennsylvania State University

Robert Collins, MD • 2004
University of Texas Southwestern Medical Center at Dallas

Steven Collins, MD • 2004
Fred Hutchinson Cancer Research Center

Kenneth Cooke, MD • 2002
University of Michigan

Kenneth Cooke, MD • 2004
University of Michigan

Laurence Cooper, MD, PhD • 2003
City of Hope National Medical Center

Richard D’Andrea, PhD • 2004
Child Health Research Institute

Bryant Darnay, PhD • 2002
University of Texas M.D. Anderson Cancer Center

Bhavana Dave, PhD • 1999
University of Nebraska Medical Center

Albert Deisseroth, MD, PhD • 2004
Sidney Kimmel Cancer Center

Don Diamond, PhD • 1998
City of Hope National Medical Center

Konstanze Dohner, MD • 2001
University of Ulm

Nicholas Donato, PhD • 2002
University of Texas M.D. Anderson Cancer Center

Ming-Qing Du, MD, PhD MRCPath • 2003
University of Cambridge

Elizabeth Eklund, MD • 2002
Northwestern University School of Medicine

Douglas Faller, MD, PhD • 1996
Boston University School of Medicine

Carolyn Felix, MD • 2002
Children’s Hospital of Philadelphia

Dean Felsher, MD, PhD • 2004
Stanford University School of Medicine

Robert Fenton, MD, PhD • 2001
University of Maryland

Robert Fenton, MD, PhD • 2004
University of Maryland

Adela Fielding, PhD MB BS • 2003
Mayo Clinic and Foundation

Barry Finette, MD, PhD • 2003
University of Vermont

Richard Ford, MD • 2002
University of Texas M.D. Anderson Cancer Center

Francine Foss, MD • 2000
New England Medical Center

Francine Foss, MD • 2005
New England Medical Center

Arthur Frankel, MD • 1998
Wake Forest University

Patricia Fraser, MD • 2001
CBR Institute of Biomedical Research, Inc.

Arnold Freedman, MD • 2001
Dana-Farber Cancer Institute

Ephraim Fuchs, MD • 2002
Johns Hopkins University School of Medicine

Spencer Gibson, PhD • 2002
University of Manitoba

D. Gary Gilliland, MD, PhD • 2003
Brigham and Women’s Hospital

Wayne Godfrey, MD • 2004
University of Minnesota

Daniel Gold, PhD • 2000
Sidney Kimmel Cancer Center

Jianlin Gong, MD • 2001
Boston University School of Medicine

Jianlin Gong, MD • 2004
Boston University School of Medicine

Richard Gorlick, MD • 2000
Memorial Sloan-Kettering Cancer Center

Stephen Gottschalk, MD • 2004
Baylor College of Medicine

Steven Grant, MD • 2001
Virginia Commonwealth University

Steven Grant, MD • 2003
Virginia Commonwealth University

Timothy Greiner, MD • 2001
University of Nebraska Medical Center

Ian Harmer, PhD • 2005
University of Cambridge

Mark Hacanay, MD, PhD • 1999
Memorial Sloan-Kettering Cancer Center

Ronald Hoffman, MD • 2000
University of Illinois at Chicago

Marshall Horwitz, MD, PhD • 2000
University of Washington

Frank Hsu, MD • 2002
Yale University School of Medicine

Michael Jensen, MD • 2002
City of Hope National Medical Center

Daniel Johnson, PhD • 2000
University of Pittsburgh

Richard Junghans, MD, PhD • 1999
Beth Israel Deaconess Medical Center

Richard Junghans, MD • 2002
Beth Israel Deaconess Medical Center

Gregory Kato, MD • 2000
Johns Hopkins University School of Medicine

Emmanuel Katsanis, MD • 1999
University of Arizona

Thomas Kipps, MD, PhD • 2004
University of California at San Diego

Guenter Kocher, MD, PhD • 2001
Memorial Sloan-Kettering Cancer Center

Krishna Komanduri, MD • 2001
University of Texas M.D. Anderson Cancer Center

Marina Konopleva, MD, PhD • 2002
University of Texas M.D. Anderson Cancer Center

Stephen Kornblau, MD • 2000
University of Texas M.D. Anderson Cancer Center

Steven Kornblau, MD • 2003
University of Texas M.D. Anderson Cancer Center

22 Dr. Afsar-Kharghan is funded by a generous gift from the MPD Foundation in partnership with Friends of Essential Thrombocythemia, Inc. and The Leukemia & Lymphoma Society.

23 Dr. Banker is funded by a generous gift to the Society from The Chuck Griffin Memorial Research Program.

24 Dr. Bhatia is funded by a generous gift to the Society from The Chuck Griffin Memorial Research Program.
Dr. Modak is funded by a generous gift to the Society from an anonymous donor.

Dr. Rafii is funded by a generous gift to the Society from John Gado Charitable Trust.

Dr. Rosenblatt is funded in part by a generous gift to the Society from The Gold-Diggers, Inc.

Dr. Shizuru is funded by a generous gift to the Society from the Jim Jacobs Charitable Foundation and the Jim Jacobs Endowment Research Fund.

Dr. Velardi is funded by a generous gift to the Society from an anonymous donor.

Dr. Vitetta is funded by a generous gift to the Society from St. Valentine's Day Luncheon & Style Show.

Dr. Wittberg is funded by a generous gift to the Society from the Jim Jacobs Charitable Foundation and the Jim Jacobs Endowment Research Fund.
Medical and Scientific Advisors

Alan M. Gewirtz, MD, Chair • 2003
University of Pennsylvania School of Medicine

Beverly S. Mitchell, MD, Vice Chair • 2003
University of North Carolina at Chapel Hill
School of Medicine

Kenneth C. Anderson, MD† • 2003
Dana-Farber Cancer Institute

Ellin Berman, MD • 2004
Memorial Sloan-Kettering Cancer Center

David Bodine, PhD • 2003
National Institutes of Health

Paul Calabresi, MD • 2005
Brown University School of Medicine

Michael Caligiuri, MD • 2003
The Ohio State University

Curt I. Civin, MD • 2004
Johns Hopkins Comprehensive Cancer Center

Alan D. D’Andrea, MD • 2004
Dana-Farber Cancer Institute

Brian Druker, MD • 2004
Oregon Health & Science University, L592

Stephen G. Emerson, MD, PhD • 2004
University of Pennsylvania

James D. Griffin, MD • 2003
Dana-Farber Cancer Institute

Armand Keating, MD • 2003
Princess Margaret Hospital

Richard J. O’Reilly, MD • 2003
Memorial Sloan-Kettering Cancer Center

David G. Poplack, MD • 2003
Elise C. Young Professor of Pediatrics
Baylor College of Medicine

Joel Rappaport, MD • 2004
Yale University School of Medicine

Steven T. Rosen, MD • 2003
Robert H. Lurie Comprehensive Cancer Center

Naomi Rosenberg, PhD • 2004
Tufts University School of Medicine

Margaret A. Shipp, MD • 2003
Dana-Farber Cancer Institute

Cheryl L. Willman, MD • 2004
University of New Mexico Cancer Center

Chairman & President’s Campaign

Margaret Anderson
Jim & Lynn Beck
John & Frances Beck Family Foundation
Alexandra Mayes Birnbaum
Stanley E. Brown
Michael Copley
Bruce Douglass
H. James Douglass
Frances M. Fox, RN, MSN
Hildegarde D. Becher Foundation
John A. Geoghegan
Susan Ann Glass
Keith P. Harenda
Steven L. Hooker
Lynn C. Hoover
Dwayne Howell
Dan J. Jordanger
Judith E. Karp, MD

Endowment Funds

GlaxoSmithKline Foundation & GlaxoSmithKline, Inc. Research Fund
Jim Jacobs Leukemia Research Fund
Vrushali Ranadive Fellowship Fund
Charlotte Meyers Research Fund
Reich Educational Fund
de Villiers Endowment Fund
Thomas M. Ford Memorial Fund
Mary & Robert Bronstein Memorial Fund
The Virginia Major Brooks Memorial Endowment Fund
Donors

Research

$1,000,000 and above
Anonymous
United Food & Commercial Workers
International Union

$100,000 – $499,999
Diamond Ball/Ed Heitz Memorial
Research Fund
F.M. Kirby Foundation
General Motors Foundation
Quest For the Cure Research Fund
The Bertelsen Family
The Jim Jacobs Charitable Foundation, Inc.
The Douglas Kroll Research Program
The Newman Foundation
Eugene E. Schmitt
The Stephen Birnbaum Foundation
Sugar Lakes Foundation
Swing For A Cure
The Beck Family Trust
The Darcy Valentine Research Fund
The Gail Cohen Leukemia Fund
The Gold-Diggers, Inc.
The Lightner Sams Foundation, Inc.
The Mary D. Averbuck Memorial
Research Fund
The Palmer Foundation
The Remillard Family Foundation, Inc.
The Richard D. Frisbee III Foundation
Mr. & Mrs. Gillis Thomas
Terry & Ron Unkefer
Tony Leffingswell Foundation
WAVA Corporation
William A. Berry & Son, Inc.

Bone Marrow

$10,000 – $49,999
10K Club
J.P. McCarthy Foundation
Rotary District 5170
The Perfect Match Golf Classic

Patient Services

$1,000,000 and above
Novartis Pharmaceuticals
$100,000 – $499,999
Genentech, Inc.
IDEA Pharmaceuticals
Ortho Biotech Products, L.P.
Susan Lang Foundation
$50,000 – $99,999
GlaxoSmithKline Inc.
The Kutz Foundation

$10,000 – $49,999
Amgen
Annunziata Sanguinetti Foundation
Community Foundation of Silicon Valley
Dr. & Mrs. Michael Copley
Five Bridges Foundation
New York State Department of Health
on behalf of Senator Charles Fuschillo
New York State Department of Health
on behalf of Senator Carl Marcellino
Purdue Pharma L.P.
Sanofi-Synthelabo, Inc.
The Angels of Charity, Inc.
The Gzik Foundation
WAVA Incorporated
WB33 Kids Fund, A Fund of the
McCormick Tribune Foundation
WGNTV Children’s Charities

Total Program

$100,000 – $499,999
Anonymous
J.P. Morgan Chase and Company
Rush Limbaugh
$50,000 – $99,999
13th Annual San Antonio Golf Classic/
Bruce Hendin
John & Violaine Bernbach
Clarissa & Edgar Bronfman, Jr.
Mr. Donald DeWees, Sr.
Mr. & Mrs. Nicholas Ferrara III
Mr. & Mrs. Eugene F. Hovnanian
James R. Kuse Foundation
Motive Communications, Inc.
Quad/Graphics, Inc.
Sun Microsystems
The Estate of Georgia Beebee
The Gap
The Madoff Family
The Victor E. and Caroline E. Schutte
Foundation
Michael Voute
$10,000 – $49,999
Adobe
Alice Bien Foundation
Alverna M. Cornell Foundation
Anonymous
Todd Appelbaum
Archer Daniels Midland Foundation
Carole Baxter
Becton, Dickinson and Co. (BD)
Bill Kay Chevrolet
Alexandra Mayes Birnbaum
C. Scott Bruin
Peter Buttenweiser
Blue Cross Blue Shield Caring Program
For Children Foundation
Boeing Houston Employees Fund
Cadence
Community Foundation for the National
Capital Region
Computer Associates
Dana Corporation Foundation
Mr. & Mrs. Edward DeBartolo & Family
Charles & Nathalie de Gunzburg
Mr. & Mrs. Robert DuHadaway
Mark & Jennifer Edwards
Electronic Arts
Employees Community Fund of Boeing
St. Louis
Thomas Evans
Financing Alternatives, Inc.
Fisher Chrysler-Kia, Yuma AZ
Floretine Camenisch Trust
Ken Gardiner
Georgia Classic Rides
Georgia Power Foundation
Harry & Jeanette Weinberg Foundation, Inc.
Highmark BlueCross BlueShield
Freddie Hoffman
Dawn & Mike Hoover
Mary Horst
Stephanie & Randy Imhoff
Henry A. Jackson
Johnson & Johnson
J.T. Tai & Co. Foundation, Inc.
Juniper Networks’ Company
Thomas & Judith Kalen
Robert Kagle
Leslie Elliot Krause, Esq.
Rob LaRoque & Carole Clause
Paul & Christine Levy
Dan & Cynthia Lufkin
Mark Grace Foundation
Mark E. Mason
Carolyn McKown
John Mezey
Menard Family Foundation
Merrill Lynch & Co.
Michael A. O’Bannon Foundation
Matt Millen
Mike Munchak
Microsoft
Muriel McBrien Kauffman Foundation
Donald & Susana Newhouse
Christopher Noble
OXB, Kiwanis
Oracle
Peter Dartley Charitable Trust
Mr. & Mrs. Edward J. Quinn, Jr.
Dr. & Mrs. Richard Raizman
James Resnik
Richard E. Salomon &
Laura Landro Salomon
Samuel C. Cantor Charitable Trust
Sarver Charitable Trust
Stephen A. & Christine Schwarzman
continued
Sponsor and Promotion Partnerships

Sponsorships

Institutions or individuals that support a Society event.

$500,000 – $999,999
Verizon

$100,000 – $499,999
American Airlines
Burlington Coat Factory
Cub Food Stores
Finish Line
Nike
Rhubarb Jones
Volvo Cars of North America, LLC
WWAY-FM Eagle 106.7

$50,000 – $99,999
Berlex Oncology
Clif Bar, Inc.
Ruth Granat
Indianapolis Power & Light Company
Michael Jordan
Medical Mutual
Michael McCarthy Foundation
Power Corporation of Canada
Rudy Project
Runner's World
Seagate
Sweet 'N Low/Cumberland Packing Corp.
The Cleveland Clinic Foundation
The Sallie Mae Fund
The Tatiana Simone Foundation
University Hospitals Health Systems
WCNN-AM 680 The Fan

$10,000 – $49,999
Abbott International/Ross Laboratories
ABM Janitorial Services
Accenture
Acorda, Inc.
Akin, Gump, Strauss, Hauer & Feld LLP
Alaska Airlines
Alcalde & Fay
American Investors
AMS
Anchorage Daily News
Anheuser Busch Companies
Anteon International Corporation
Arnold & Porter LLC
AT&T
Aventis Pharmaceuticals
BAE SYSTEMS
Banc of America Capital Management
Banc of America, LLC
Bank of America

Bank of Tokyo-Mitsubishi
Barton Protective Services Inc.
Baxter Healthcare Corp.
Bay Area Labor
Bay Partners
BB&T Children's Charities
BearingPoint, Inc.
Beers & Cutler
Deborah Bennett
Berlex Laboratories
Bert Smith & Co.
Janice Brandt
Bowne & Company
Brown Investment Advisory & Trust Company
California-Nevada Operating Engineers
Campbell & Company
Canary Charitable Foundation
Capital One
Caremark RX
Carr Futures
Carrella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein
Cartier's
CB Richard Ellis
CIBC Oppenheimer
Celgene Corporation
Cell Therapeutics, Inc.
Chick-fil-A
Choice Hotels International, Inc.
Cingular Wireless
Clark/Bardes Consulting
Bill & Bonnie Clark
Clarkston Consulting
Columbia Lakes Golf & Conference Center
Comcast
Commerce Bank
CompUSA
Corinthian Manufacturing, Inc.
Costco
Coventry Health Care
Credit Suisse First Boston Corporation
CRIMI MAE, Inc.
Cruise Industry Charitable Foundation
Cumberland Packing Corp./Sweet 'N Low
DaimlerChrysler Corporation Fund
DaimlerChrysler
Danaher Corporation
DARCARS
DBD Worldwide Communications Group, Inc.
Mr. & Mrs. Edward DeBartolo & Family
Deloitte & Touche LLP
Deutsche Bank
Dewey Ballantine LLP
John & Leslie Dorman
Dresser Industries
Duffy Mechanical Corp. – An EMCOR Company

Edgar M. Cullman & Edgar M. Cullman Jr. & their Family Foundations
Edward & Susan Blumenfeld Foundation
Mark & Jennifer Edwards
EFW, Inc.
El Paso
ELG Haniel Metals Corp.
Enterprise Rent-A-Car Foundation
Ernst & Young LLP
Extreme Networks
F. Hoffman-La Roche, Ltd.
Mr. & Mrs. David B. Falk
Family Home Providers
Feder Semo & Bard, P.C.
Fidelity National Title Insurance Company
FINDS
Finocchio Wine Company
Floors to Go
Florida Hospital Cancer Institute
Focus Healthcare Management, Inc.
Food Service Management – Dominic Abbott
Foodland Independent Retailers
Frank & Susan Withhun
Fred O. Funkhouser
Freddie Mac
Fujisawa
GEICO
GEICO Philanthropic Foundation
Geni, LLC
Genentech BioOncology
Genentech, Inc.
General Dynamics
General Electric
General Motors/North American Operations
Gibson Musical Instruments
Goldman Sachs & Co.
Greenberg Traurig LLP
Harry & Jeanette Weinberg Foundation
HCC Insurance Holdings, Inc.
Hewitt Associates
HITT Contracting Inc.
John & Laura Hirschmann
Hoag Hospital
Holiday Stationstores
Howrey Simon Arnold & White LLP
IDEC Pharmaceuticals
ILEX Oncology, Inc.
Information Management Consultants, Inc.
Integrity Healthcare Services
Intelsat
Jan M. & Eugenia Krol Charitable Foundation
JFK Medical Center
JPMorgan Chase & Company
K-Designer's
Keith & Rose-Lee Reinhard Family Foundation
John Kellenyi
Kirkland and Ellis

Donors (continued)

Edith M. Schweekendieck Trusts
Stanley E. Brown Family Foundation
Garrett Stauffer, CPA
John R. Stein
Tom Sullivan
The Ambrose and Gladys Bowyer Foundation
The Crecin Foundation
The Dan Jansen Foundation, Inc.
The Hanley Foundation
The Hellis Foundation
The Ingeborg Foundation
The JP Morgan Chase Foundation
The Kritchman Family Foundation
The Lebensfeld Foundation
The Sandra Atlas Bass and Edythe & Sol G. Atlas Fund
The Sidney, Milton and Leema Simon Foundation
The Strain Foundation
Christy Tolar
Mr. & Mrs. Robert Tschudy
Verizon
Wells Fargo
Wyner-Stokes Family Foundation
Mark Zurack & Kathy Ferguson
The Legacy Circle honors those who have included the Society in an estate plan.

Hugh Albroa
Peter Alexer
Bruce Allen
Fay Allen
Marjorie Anderson
Mr. and Mrs. David Andrews
James and Eileen Andrews
Kristi Anys
Lorae P. Aumack
Mr. and Mrs. Jay Barrows
Mr. and Mrs. Edwin J. Beckley, Jr.
Angelo Bardi
Claudia and Stephen Barto, Jr.
Dennis Beardsley
Ryan Beagin
Ari Berkowitz
Clyde S. Billman
Alexandra Mayes Birnbaum
The Stephen Birnbaum Foundation
Margaret Black
Christopher Blum
Lori Blum
Sally Blume
Robert H. and Janet Bohannon
James Bolton
Mart Bort
William Boyd
Wilburn Brewer, Jr.
Judith Arner Brown
Richard Cuhl
Mary Carver
Betty Chalmers
Robert Charon
Pasquale R. Cheche
Thomas Cheek
Sylvia Clemenson
Paul and Nancy Clendening
Katherine Wegerman-Cook
Dr. Anthony Cortese
Marianne Cotter
Raymond Cox
Marilyn J. Crohan
Michelle Cronwell
Edmund D'Allesio
Judy Davis
Dr. and Mrs. Michael L. Dean
Carolyn Dee
David and Connie Dimling
Kathy Dirckx
Joel Drake
Harry and Barbara Dunlap
John Dunn
Agnes Dury
J. Stephen Eckert
Greg Ellers
Mr. and Mrs. Jeffrey Ellena
Lynne E. Fazzi
Richard A. Fess
Harold Fennell
Harvey Fernbach, MD
Helen F. Fisher
Mr. and Mrs. James T. Fox
David Frantze
Paul N. Frimmer
Robert Faue
Albert and Gladys Gardner
Betsy Garfian
Anna Marie Gentile
John A. Geoghegan
Richard and Jacqueline Geswell
Noreen L. Giese
Heather Girard
Wade Goehring
Richard Goldberg
Wilma Gottlieb
Rebecca Ann Grajelewski
Ruth Granat
Carole Grandaw
Mr. and Mrs. Forrest Grosvenor
Dan and DaDonna Guibitz
Mr. and Mrs. Ken Haller
Keith F. Harenda
Alice Hatch
Pat Hauer
Kathleen Hays, RN, MSN
Tom and Wendy Henry
Catherine E. Hildrath
C. Brooks Hoffman
Carol Hogan
Beth Hoth
Jeanie Hoover
Lynn Hoover
John Harrison Hough
Roy Hoivinen
Dwayne Howell
Heather Hunt
Dr. Brian Hurley
William Ianniello
Joan Jarrett
Amy Johnson
Harry and Donna Johnson III
Mrs. Darden Jones
Nathan and Ruthie T. Katz
Frances Keating
Michael E. Keefe
Mr. and Mrs. Christopher J. Kearns
John B. Kelly
Michael Kerper
Annabelle King, MD
Sue Kinney-Wieland
T. Corey Kipp
Monica Klapper
Karl Koghe
Jeff and Teresa Kopietz
Carmella Kramer
Leslie Elliot Krause
Mr. and Mrs. Greg Kulm
Janet LaVere
John Lamb, Jr.
William S. Lear
Diana Lynn Lee
Gail M. Lee
Paul L. Lewis
Robert Lindsey
Harvey and Linda Litofsky
Geoffrey Lombard
Mr. and Mrs. FF. Michael Lynch
Ida Malena
Georgia Davidis Malone
Maria Maramag
Dr. and Mrs. Stanley N. Marks
Greg Martin
William Martin
Mark E. Mason
Joan Maves
Robert and Marnee Maylone
John and Patty McDonald
Thomas and Ollive McDonald
Dorothy McCann
Marilyn McFadden
Sylvia McGovern
Carolyn E. McKown
Tina Marie Milligan
Suzy Minkoff
Joshua Mitchell, MD
Ted Mociun
Michael and Tammy Moloy
Dennis F. Moore, MD
Joan Moran
Mr. and Mrs. Thaddee F. Moreau
Dennis Morris
James Morton
Robert J. Myole
Frank Mungo
Suzanne J. Muntzing
Rodman N. Myers
Robert J. Myette
The Honorable Robert H. Newman
Robert C. Niles
Edward Nofer III
Jason North
Richard F. Nourie
Carolyn and Jerry O'Hara
Edward D. O'Malley
MRS. Harry O'Toole
Margaret Olmaz
George Omiros
Rosemary Ophbroek
Mary J. Oyer
Jacqueline Anne Palmenberg
Mr. and Mrs. Paul Paluch
Rosa Pena
Stephen M. Peters
Leslea S. Pidgeon
William Pike
George Pooley
Larry Pyles
David B. and Toni Quinty
Marty Rauch
Richard and Kathy Reader
Helen Dess Reed
James Relkin
David Rice
Marilyn Richardson
Ernest Rause
Selena Rogers
Judith A. Ross
Seth and Carolyn Rudnick
Joseph Russell
Kevin B. Ryan
William H. Sachs
Delora Sanfilippo
Mr. and Mrs. Robert Smith
Russell D. Smith
Nicoia Sobolewski
Jeffrey and Angela Solomonson
Richard and Katherine Reader
Helen Dess Reed
James Relkin
David Rice
Marilyn Richardson
Ernest Rause
Selena Rogers
Judith A. Ross
Seth and Carolyn Rudnick
Joseph Russell
Kevin B. Ryan
William H. Sachs
Delora Sanfilippo
Mr. and Mrs. Robert Smith
Russell D. Smith
Nicoia Sobolewski
Jeffrey and Angela Solomonson
John C. Sorrell
Elda Spano
James E. Sparkes
Barbara A. Spiegel
Thomas and Joanne Spink
Mark and Carol Spisak
Paula and Phillip Stone
Marcie Summerlin
Dolores Swirin
Merideith Tall
Stewart Teichman
Gracie Thompson
Patricia Trosclair
Heather Turnbull
Joseph Verdirame, MD
Bert Vignes
Philip F. Warner
Mr. and Mrs. Rubin Wallach
John E. Walter
Paul Weiden, MD
Phyllis Weil
Vicki Weiland
Deborah Weinstein
James A. Weinberg
Paul and Annie Weiss
Mr. and Mrs. John Wempe
Dr. and Mrs. Stanley A. White
Carl and Hillary Whitley
Don Wier
Clara Wood
Mr. and Mrs. Douglas Young
Joseph Yurfest
Katherine Zell-Cherry

Anonymous (127)

† Deceased
Independent Auditors’ Report

Board of Trustees
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated statement of financial position of The Leukemia & Lymphoma Society, Inc. (the Society) as of June 30, 2003, and the related consolidated statements of activities, cash flows, and functional expenses for the year then ended. These consolidated financial statements are the responsibility of the Society’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. The prior year summarized comparative information has been derived from the Society’s 2002 consolidated financial statements and, in our report dated October 10, 2002, we expressed an unqualified opinion on those statements.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2003, and the changes in its net assets and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

KPMG LLP

October 6, 2003
New York, NY
## Consolidated Statement of Financial Position

**The Leukemia & Lymphoma Society, Inc.**  
**June 30, 2003**  
(with comparative amounts at June 30, 2002)  
(in thousands)

### Assets

- **Cash and cash equivalents**  
  2003: $31,694  
  2002: $9,628
- **Accounts receivable**  
  2003: 382  
  2002: 849
- **Legacies and contributions receivable (note 2)**  
  2003: 7,073  
  2002: 4,440
- **Prepaid expenses**  
  2003: 3,437  
  2002: 3,537
- **Investments, at fair value (note 3)**  
  2003: 60,779  
  2002: 72,194
- **Equipment and leasehold improvements, less accumulated depreciation and amortization of $5,087 and $4,071**  
  2003: 3,896  
  2002: 4,457

**Total assets**  
2003: $107,261  
2002: $95,105

### Liabilities and Net Assets

**Liabilities:**
- **Accounts payable and accrued expenses**  
  2003: $13,290  
  2002: $11,348
- **Deferred revenue**  
  2003: 5,291  
  2002: 4,054
- **Grants payable (note 4)**  
  2003: 43,702  
  2002: 40,261

**Total liabilities**  
2003: 62,283  
2002: 56,263

**Net assets:**
- **Unrestricted**  
  2003: 38,008  
  2002: 34,903
- **Temporarily restricted (note 7)**  
  2003: 4,786  
  2002: 2,819
- **Permanently restricted (note 7)**  
  2003: 2,184  
  2002: 1,120

**Total net assets**  
2003: 44,978  
2002: 38,842

**Total liabilities and net assets**  
2003: $107,261  
2002: $95,105

*See accompanying notes to consolidated financial statements.*
# Consolidated Statement of Activities

*The Leukemia & Lymphoma Society, Inc.*  
**Year ended June 30, 2003**  
*(with summarized totals for the year ended June 30, 2002)*  
*(in thousands)*

## Revenue

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>2003</th>
<th>Total</th>
<th>2002</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Campaign contributions</strong></td>
<td>$181,606</td>
<td>$3,663</td>
<td>$164</td>
<td>$185,433</td>
<td>$174,286</td>
<td></td>
</tr>
<tr>
<td><strong>Less direct donor benefit costs</strong></td>
<td>(27,370)</td>
<td>-</td>
<td>-</td>
<td>(27,370)</td>
<td>(27,747)</td>
<td></td>
</tr>
<tr>
<td><strong>Net campaign contributions</strong></td>
<td>154,236</td>
<td>3,663</td>
<td>164</td>
<td>158,063</td>
<td>146,539</td>
<td></td>
</tr>
<tr>
<td><strong>Legacies</strong></td>
<td>2,014</td>
<td>-</td>
<td>900</td>
<td>2,914</td>
<td>4,206</td>
<td></td>
</tr>
<tr>
<td><strong>Net interest and dividend income (note 3)</strong></td>
<td>1,561</td>
<td>-</td>
<td>59</td>
<td>1,620</td>
<td>2,063</td>
<td></td>
</tr>
<tr>
<td><strong>Net decrease in fair value of investments</strong></td>
<td>(560)</td>
<td>(198)</td>
<td>-</td>
<td>(758)</td>
<td>(2,907)</td>
<td></td>
</tr>
<tr>
<td><strong>Grant refunds</strong></td>
<td>2,119</td>
<td>-</td>
<td>-</td>
<td>2,119</td>
<td>1,607</td>
<td></td>
</tr>
<tr>
<td><strong>Net assets released from restrictions</strong></td>
<td>1,557</td>
<td>(1,557)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>Total revenue</strong></td>
<td>160,927</td>
<td>1,967</td>
<td>1,064</td>
<td>163,958</td>
<td>151,508</td>
<td></td>
</tr>
</tbody>
</table>

## Expenses (note 8)

### Program Services:

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>2003</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Research</strong></td>
<td>41,738</td>
<td>-</td>
<td>-</td>
<td>41,738</td>
<td>39,172</td>
</tr>
<tr>
<td><strong>Patient and community service</strong></td>
<td>42,030</td>
<td>-</td>
<td>-</td>
<td>42,030</td>
<td>41,843</td>
</tr>
<tr>
<td><strong>Public health education</strong></td>
<td>26,217</td>
<td>-</td>
<td>-</td>
<td>26,217</td>
<td>28,554</td>
</tr>
<tr>
<td><strong>Professional education</strong></td>
<td>8,377</td>
<td>-</td>
<td>-</td>
<td>8,377</td>
<td>7,306</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td>118,362</td>
<td>-</td>
<td>-</td>
<td>118,362</td>
<td>116,875</td>
</tr>
</tbody>
</table>

### Supporting Services:

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>2003</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Management and general</strong></td>
<td>12,029</td>
<td>-</td>
<td>-</td>
<td>12,029</td>
<td>10,573</td>
</tr>
<tr>
<td><strong>Fund raising</strong></td>
<td>27,431</td>
<td>-</td>
<td>-</td>
<td>27,431</td>
<td>27,726</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td>39,460</td>
<td>-</td>
<td>-</td>
<td>39,460</td>
<td>38,299</td>
</tr>
</tbody>
</table>

**Total expenses**  
157,822

**Change in net assets**  
3,105  
1,967  
1,064  
6,136  
(3,666)

## Net Assets

<table>
<thead>
<tr>
<th></th>
<th>2003</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Beginning of year</strong></td>
<td>34,905</td>
<td>38,842</td>
</tr>
<tr>
<td><strong>End of year</strong></td>
<td>$38,008</td>
<td>$44,978</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
Consolidated Statement of Cash Flows

The Leukemia & Lymphoma Society, Inc.
Year ended June 30, 2003
(with comparative amounts for the year ended June 30, 2002)
(in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2003</th>
<th>2002</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$ 6,136</td>
<td>$(3,666)</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net decrease in fair value of investments</td>
<td>758</td>
<td>2,907</td>
</tr>
<tr>
<td>Permanently restricted contributions, net of related receivables in 2003</td>
<td>(164)</td>
<td>(30)</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>1,362</td>
<td>1,714</td>
</tr>
<tr>
<td><strong>Net cash provided by operating activities</strong></td>
<td>12,046</td>
<td>4,206</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2003</th>
<th>2002</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from investing activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchases of equipment and leasehold improvements</td>
<td>(801)</td>
<td>(1,722)</td>
</tr>
<tr>
<td>Sales (purchases) of investments, net</td>
<td>10,657</td>
<td>(819)</td>
</tr>
<tr>
<td><strong>Net cash provided by (used in) investing activities</strong></td>
<td>9,856</td>
<td>(2,541)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2003</th>
<th>2002</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from financing activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Permanently restricted contributions, net of related receivables in 2003</td>
<td>164</td>
<td>30</td>
</tr>
<tr>
<td><strong>Net cash provided by financing activities</strong></td>
<td>164</td>
<td>30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2003</th>
<th>2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net increase in cash and cash equivalents</td>
<td>22,066</td>
<td>1,695</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of year</td>
<td>9,628</td>
<td>7,933</td>
</tr>
<tr>
<td><strong>Cash and cash equivalents at end of year</strong></td>
<td>$ 31,694</td>
<td>$ 9,628</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
### Consolidated Statement of Functional Expenses

**The Leukemia & Lymphoma Society, Inc.**  
**Year ended June 30, 2003**  
**(with comparative totals for the year ended June 30, 2002)**  
**(in thousands)**

<table>
<thead>
<tr>
<th>Program Services</th>
<th>Supporting Services</th>
<th>Total</th>
<th>Direct donor benefit costs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2003</td>
<td>2002</td>
</tr>
<tr>
<td>Awards and grants</td>
<td></td>
<td>$ 40,101</td>
<td>$ 37,648</td>
</tr>
<tr>
<td>Financial aid to patients</td>
<td>5,651</td>
<td>3,631</td>
<td>3,631</td>
</tr>
<tr>
<td>Salaries</td>
<td>453</td>
<td>17,219</td>
<td>8,317</td>
</tr>
<tr>
<td>Employee benefits and taxes (note 5)</td>
<td>76</td>
<td>3,542</td>
<td>2,105</td>
</tr>
<tr>
<td>Occupancy (note 6)</td>
<td>18</td>
<td>2,254</td>
<td>1,350</td>
</tr>
<tr>
<td>Insurance</td>
<td>8</td>
<td>204</td>
<td>152</td>
</tr>
<tr>
<td>Telephone</td>
<td>13</td>
<td>911</td>
<td>651</td>
</tr>
<tr>
<td>Travel</td>
<td>21</td>
<td>713</td>
<td>413</td>
</tr>
<tr>
<td>Printing and supplies</td>
<td>166</td>
<td>4,277</td>
<td>5,085</td>
</tr>
<tr>
<td>Equipment rentals and maintenance</td>
<td>6</td>
<td>599</td>
<td>364</td>
</tr>
<tr>
<td>Postage and shipping</td>
<td>68</td>
<td>2,119</td>
<td>2,985</td>
</tr>
<tr>
<td>Meetings</td>
<td>371</td>
<td>1,131</td>
<td>555</td>
</tr>
<tr>
<td>Professional fees</td>
<td>407</td>
<td>4,625</td>
<td>3,686</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>14</td>
<td>359</td>
<td>217</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>16</td>
<td>466</td>
<td>337</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$ 41,738</strong></td>
<td><strong>$ 42,030</strong></td>
<td><strong>$ 26,217</strong></td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
Notes to Consolidated Financial Statements
The Leukemia & Lymphoma Society, Inc.
Year ended June 30, 2003
(with comparative amounts as of and for the year ended June 30, 2002)

1. Organization and Significant Accounting Policies

Organization
The Leukemia & Lymphoma Society, Inc. (the “Society”) is a national
not-for-profit health agency dedicated to seeking the cause and eventual
cure of leukemia, lymphoma, Hodgkin’s disease and myeloma and improving
the quality of life of patients and their families. The Society’s principal
activities, which are conducted through its local chapters and the Home Office,
include: awarding research grants; facilitating psychosocial support groups;
providing financial aid to patients; answering phone requests for blood-related
cancer information made to the Society’s Information Resource Center;
and disseminating educational information about blood-related cancers
in the form of publications, internet sites and symposia sponsorship
for both the medical community and the general public.

Tax-Exempt Status
The Society qualifies as a charitable organization as defined by Internal
Revenue Code Section 501(c)(3) and, accordingly, is exempt from federal income
taxes under Internal Revenue Code Section 501(a). Additionally, since the Society
is publicly-supported, contributions to the Society qualify for the maximum
charitable contribution deduction under the Internal Revenue Code.

Principles of Consolidation
The accompanying consolidated financial statements include the accounts
of the Society, which encompasses the Home Office of the Society and its
sixty chapters, as well as its not-for-profit affiliates, Leukemia Society Research
Programs, Inc. and Leukemia Society of America Research Foundation.
All significant inter-company and intra-Society accounts and transactions
have been eliminated in consolidation.

Net Asset Classifications
To ensure observance of limitations and restrictions placed on the use
of resources available to the Society, funds that have similar characteristics
have been classified into three net asset categories as follows:

Unrestricted net assets: Consist of funds that are fully available,
at the discretion of the Board of Trustees, for the Society to utilize
in any of its programs or supporting services.

Temporarily restricted net assets: Consist of funds that are restricted
by donors for a specific time period or purpose, as well as amounts
relating to term endowment or deferred giving arrangements in which
the funds must be maintained intact over the lifetimes of the donors.

Permanently restricted net assets: Consist of funds that contain
donor-imposed restrictions requiring that the principal be invested
in perpetuity and that only the income be used. Income earned on these
funds may be unrestricted or temporarily restricted, depending upon
the donor-imposed restrictions.

Contributions and Deferred Revenue
Contributions are recorded as revenue, at their fair value, when received
or promised unconditionally. Contributions received with donor restrictions
that limit their use are reported as either temporarily or permanently restricted
revenue. When a donor restriction is met through the passage of time or fulfill-
ment of a purpose restriction, temporarily restricted net assets are reclassified
to unrestricted net assets and reported in the statement of activities as net assets
released from restrictions. Temporarily restricted contributions that are received
and expended in the same period are reported as unrestricted contributions.
Conditional contributions are recognized as revenue when the conditions have
been substantially met.

Deferred revenue includes amounts received for special events that will be held
subsequent to the fiscal year-end.

Donated Services
A substantial number of volunteers have made significant contributions of their
time to help develop the Society’s programs and activities. The value of such
volunteer services has not been reflected in the accompanying consolidated
financial statements as it does not meet the criteria for revenue recognition.

Cash Equivalents
Cash equivalents consist of money market accounts and short-term investments
with a maturity of three months or less from date of purchase, except
for amounts held for long-term purposes reported as investments.

Equipment, Leasehold Improvements and Depreciation
Equipment and leasehold improvements are recorded at cost, if purchased,
or at fair value at date of donation, if contributed, and are depreciated
or amortized using the straight-line method over the estimated useful lives
of the assets or the terms of the leases, if shorter.

Estimates
The preparation of financial statements in conformity with generally accepted
accounting principles requires the Society’s management to make estimates
and assumptions that affect the amounts reported in the financial statements
and accompanying notes. Actual results could differ from those estimates.

Summarized Financial Information
The financial statements are presented with 2002 comparative information.
With respect to the statement of activities, such prior year information is not
presented by net assets class and, in the statement of functional expenses, 2002
expenses by object are presented in total rather than by functional category.
Accordingly, such information should be read in conjunction with the Society’s
2002 financial statements from which the summarized information was derived.
2. Legacies and Contributions Receivable

The Society's legacies and contributions receivable at June 30, 2003 and 2002 consist of unconditional promises to give and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Amounts are scheduled to be received as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2003</th>
<th>2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>$5,293</td>
<td>$3,649</td>
</tr>
<tr>
<td>1 to 5 years</td>
<td>1,730</td>
<td>600</td>
</tr>
<tr>
<td>After 5 years</td>
<td>132</td>
<td>333</td>
</tr>
<tr>
<td></td>
<td>7,155</td>
<td>4,582</td>
</tr>
<tr>
<td>Less discount to present value (discount rate – 5%)</td>
<td>(82)</td>
<td>(142)</td>
</tr>
<tr>
<td>Total</td>
<td>$7,073</td>
<td>$4,440</td>
</tr>
</tbody>
</table>

3. Investments

The following is a summary of investments at June 30, 2003 and 2002 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2003</th>
<th>2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost or</td>
<td>Donated</td>
<td>Fair</td>
</tr>
<tr>
<td>Donated</td>
<td>Value</td>
<td>Value</td>
</tr>
<tr>
<td>Money market funds</td>
<td>$12,929</td>
<td>$12,929</td>
</tr>
<tr>
<td>Corporate notes and bonds</td>
<td>28,711</td>
<td>29,285</td>
</tr>
<tr>
<td>Common stocks and mutual funds</td>
<td>20,085</td>
<td>18,083</td>
</tr>
<tr>
<td>U.S. Government obligations</td>
<td>402</td>
<td>424</td>
</tr>
<tr>
<td>Other</td>
<td>58</td>
<td>58</td>
</tr>
<tr>
<td>Total</td>
<td>$62,185</td>
<td>$60,779</td>
</tr>
</tbody>
</table>

Debt and equity securities are recorded at fair value as determined by quoted market prices. Mutual funds are recorded at fair value using published unit values. Investment expenses of $275,000 and $305,000 have been netted against interest and dividend income for the years ended June 30, 2003 and 2002, respectively.

4. Awards and Grants

Awards and grants for research are recognized as expense in the year approved by the Society's Board of Trustees. Multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of the Society's Board of Trustees. In addition to unconditional grants payable of $43,702,000 at June 30, 2003, the Society has grant commitments of $63,938,000 that are conditioned upon future events and, accordingly, are not recorded.

5. Pension Plan

The Society has a noncontributory, defined contribution 403(b) pension plan covering all employees meeting age and service requirements. Contributions are based on a percentage of each eligible employee's salary and years of service. Expense under this plan aggregated $1,749,000 and $1,644,000 for the years ended June 30, 2003 and 2002, respectively.

6. Occupancy Expense and Lease Commitments

The leases for premises which the Society's Home Office and chapters occupy expire on various dates through September 30, 2012 and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses and utilities.

The approximate minimum future annual rental commitments are summarized as follows (in thousands):

<table>
<thead>
<tr>
<th>Year ended June 30</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>Thereafter</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5,155</td>
<td>4,738</td>
<td>3,878</td>
<td>3,096</td>
<td>2,571</td>
<td>5,825</td>
<td>25,261</td>
</tr>
</tbody>
</table>

7. Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2003 and 2002 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2003</th>
<th>2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temporarily</td>
<td>Permanently</td>
<td>Temporarily</td>
</tr>
<tr>
<td>Restricted</td>
<td>Restricted</td>
<td>Restricted</td>
</tr>
<tr>
<td>Research program</td>
<td>$4,075</td>
<td>$2,137</td>
</tr>
<tr>
<td>Patient service and bone marrow donor program</td>
<td>298</td>
<td>-</td>
</tr>
<tr>
<td>Professional education program</td>
<td>21</td>
<td>47</td>
</tr>
<tr>
<td>Other programs</td>
<td>392</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>$4,786</td>
<td>$2,184</td>
</tr>
</tbody>
</table>

8. Joint Costs Allocation

In 2003 and 2002, the Society incurred joint costs for informational materials and activities that included fund raising appeals as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2003</th>
<th>2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund raising</td>
<td>$10,425</td>
<td>$11,986</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>1,172</td>
<td>1,262</td>
</tr>
<tr>
<td>Public health education</td>
<td>6,705</td>
<td>8,060</td>
</tr>
<tr>
<td>Total</td>
<td>$18,302</td>
<td>$21,308</td>
</tr>
</tbody>
</table>
National Leaders

Chairman of the Board
Norbert J. Sieber
Executive Vice President
MARC USA
Pittsburgh, PA

Vice Chairman
Frank T. Short
Short Strategy Group, Inc.
Indianapolis, IN

Vice Chairman for Medical and Scientific Affairs
Alan M. Gewirtz, MD
Stem Cell Biology & Therapeutic Program
University of Pennsylvania Cancer Center
Philadelphia, PA

Secretary/Treasurer
Donald H. Sal셔
Director of Finance
UCFW
Washington, DC

National Board of Trustees
Fay Allen
Jeffersonville, IN
Margaret H. Anderson
Managing Partner
Anderson, Bryant, Lasky & Winslow, PSC
Louisville, KY
Irwin D. Bernstein, MD
Program Head, Pediatric Oncology Program
Fred Hutchinson Cancer Research Center
Seattle, WA
Alexandra Mayes Birnbaum
New York, NY
Richard L. Bohanon
Oklahoma City, OK
Paul Calabresi, MD, MACP
Professor of Medicine & Medical Science and Chairman Emeritus, Department of Medicine
Brown University School of Medicine
Providence, RI
Robert A. “Spider” Cantley
Fremont, CA
Paul J. Cienki
VP, Finance & Information Services
Smiths Aerospace Actuation Systems
Whippany, NJ
John M. Collin, PhD
Professor of Microbiology
Tufts University School of Medicine
Boston, MA
Michael Copley
Community Liaison
Children's Hospital & Health Center
San Diego, CA
David A. Denihan
Vice President
Marsh, Inc.
Los Angeles, CA
Calvin E. Donnelly
Elliott City, MD
Bruce Douglass
Boulder, CO
Brian Drucker, MD
Division of Hematology/Medical Oncology
Oregon Health Sciences University
Portland, OR
Lawrence D. Ellis, MD
Professor of Medicine
University of Pittsburgh
Pittsburgh, PA
Stephen G. Emerson, MD, PhD
Chief, Hematology-Oncology
University of Pennsylvania School of Medicine
Philadelphia, PA
Richard A. Fess
President
Mid-Florida Agencies of Orlando, Inc.
Longwood, FL
Thomas L. Fitzpatrick
Manager of Corporate Credit
Saiet Gobain Corporation
Worcester, MA
Frances M. Fox, RN, MSN
President
Home Instead Senior Care
Mt. Laurel, NJ
David Frantz
Stimson, Morrison, Hecker, LLP
Kansas City, MO
Richard Garrison
President and Owner
Advertising Novelty Co., Inc.
Washington, DC
John A. Georgiades
Gelert and Quarratano
Purchase, NY
Susan Ann J. Glass
Richmond, VA
James D. Griffin, MD
Dana-Farber Cancer Institute
Boston, MA
Carter K. Guice, Jr.
Assistant U.S. Attorney
Eastern District of Louisiana
New Orleans, LA
Keith P. Harendo
President/Owner
KPH Construction Corp.
Milwaukee, WI
Kathleen Hays, RN, MN
Director, Inpatient Oncology Services
University of Pittsburgh Cancer Institute
University of Pittsburgh Medical Center
Pittsburgh, PA
Rex Hildre
San Antonio, TX
Steven L. Hooker
Senior VP, CFO & Treasurer
The Regency Group
Portland, OR
Lynn C. Hoover
Stinson Morrison Hecker LLP
Kansas City, MO
Thomas F. Hunter
President & CEO
Spar Performance Group
Carrollton, TX
Charles F. Inglefield
Rocky River, OH
Don J. Jordanger
Partner
Hunt & Williams
Richmond, VA
John M. Kamins
Partner
Honigman Miller Schwartz and Cohn
Detroit, MI
Judith E. Karp, MD
Professor of Medicine
Greenebaum Cancer Center
University of Maryland Medical Systems
Baltimore, MD
Elliot Katz
Belmont, CA
Michael J. Keating, MD
M.D. Anderson Cancer Center
Houston, TX
Ruth S. Keeve
Cincinnati, OH
Leslie Elliot Krause, Esq.
Law Offices of Leslie Elliot Krause
New York, NY
Marie Lauria, MSW
Clinical Associate Professor
University of North Carolina
Chapel Hill, NC
Michael L. Lawson
President
Lawrence Utilities, LLC
Indianapolis, IN
Michael W. Long, PhD
President & CEO
Volcura Therapeutics, Inc.
Ann Arbor, MI
Dennis F. Marco
North Haledon, NJ
W. Stratford May, Jr., MD, PhD
Director, Shands Cancer Center
University of Florida
Gainesville, FL
Thomas R. McDonald
Marana, AZ
Carolyn McKown
Fenton, DE
Richard H. Michalik
Naperville, IL
Beverly S. Mitchell, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC
L. Weight Moody
Deutility & Touch
Houston, TX
Dennis F. Moore, MD, FACP
Chairman, Department of Hematology-
Medical Oncology
Wichita Clinic
Wichita, KS
Virginia S. Morris
Seattle, WA
Rodman N. Myers
Of Counsel
Honigman Miller Schwartz and Cohn
Detroit, MI
Deborah R. Nix
Dulzelle, SC
Jason North
JSN Consulting
Palm Beach, FL
Mary J. Oyer
Northfield, IL
Frederic C. Parvey
Director
Altel
Jacksonville, FL
David G. Poplack, MD
Professor of Pediatrics
Baylor College of Medicine
Houston, TX
Peter J. Quessenberry, MD
Chair, Department of Research
Roger Williams Medical Center
Providence, RI
Joel Rappaport, MD
Woodbridge, CT
Martin Rauch
Owner
RE/MAX Schooldie REALTORS
Cheshire, CT
William H. Reimers
Regional VP, Medical Markets
DHS Group
Raleigh, NC
Glenn A. Reiner, Esq.
Agins, Seigel & Reiner, LLP
New York, NY
Marcie Reehar Rogell
Community Education
Children's Hospital
Columbus, OH
Naomi Rosenberg, PhD
Professor of Pathology
Tufts University School of Medicine
Boston, MA
Kevin R. Ryan
Yampolsky, Mandeloff, Silver & Co.
Philadelphia, PA
Victor Sacco
Senior Manager of Real Estate
Holiday Companies
Bloomington, MN
The Leukemia & Lymphoma Society Research Foundation

Officers
Harry Pearce, President
Chairman
Hughes Electronics Corporation
Norbert J. Sieber, Vice President
Executive Vice President
MARC USA
Chairman
The Leukemia & Lymphoma Society
Alan M. Gewirtz, MD,
Medical Vice President
Professor of Medicine & Pathology
University of Pennsylvania Cancer Center
Vice Chairman for Medical and Scientific Affairs
The Leukemia & Lymphoma Society
Dwayne Howell, Secretary-Treasurer
President & Chief Executive Officer
The Leukemia & Lymphoma Society
Tom Bertelsen, Director
Investment Banker
Andrew Madoff, Director
Bernard L. Madoff Investment Securities
Scott Zelinger, Director
Kadima Partners, LLC

Medical Advisory Board
Edward J. Benz, Jr., MD
President
Dana-Farber Cancer Institute
Donald Pinkel, MD
Chairman
Institutional Review Board
Driscoll Children's Hospital
Louis W. Sullivan, MD
President
Morehouse School of Medicine
E. Donnall Thomas, MD
Member
Fred Hutchinson Cancer Research Center
Professor of Medicine, Emeritus
University of Washington School of Medicine

Senior Staff
Dwayne Howell
President & CEO
Field & Human Resources Development
Cynthia Gardner
Executive Vice President
Field & Human Resources Development
Paul Weiss
Senior Vice President
Field Development
Leslie Chambers
Vice President
Field Development
Finance, Administration & Information Technology
John Walter
Executive Vice President & Chief Financial Officer
Finance, Administration & Information Technology
Jimmy Nangle
Vice President
Finance
Stephen B. Lucas
Chief Information Officer

Government & Legislative Affairs
George Dahlman
Vice President
Public Policy
Marketing Communications & Revenue Generation
Richard J. Geswell
Executive Vice President
Revenue & Marketing
Nancy Klein
Senior Vice President
Marketing Communications
Greg Ellers
Senior Vice President
Campaign Development
Judi Brown
Vice President
Major & Planned Gifts
Geralyn LaNeve
Vice President
Communications

Patient Services
Robin Kornhaber, MSW
Senior Vice President
Patient Services
Hildy Dillon
Vice President
Patient Services • Disease Programs
Research & Medical Programs
Marshall A. Lichtman, MD
Executive Vice President
Research & Medical Programs
Alan Kinniburgh, PhD
Vice President
Research Administration
Chapter Offices

**Alabama**
Gulf Coast Chapter
100 Chase Park South • Suite 220
Birmingham, AL 35244
Telephone: 205.909.0098

**Arizona**
Desert Mountain States Chapter
2940 E. Northern Avenue • N. E 100
Phoenix, AZ 85028
Telephone: 602.788.8622

**California**
California Chapter
701 E. Hermosa • Suite 102
Fresno, CA 93720-2929
Telephone: 559.435.1482

Greater Los Angeles Chapter
6033 West Century Boulevard • Suite 300
Los Angeles, CA 90045
Telephone: 310.216.7080

Greater Sacramento Area Chapter
3105 Fite Circle • Suite 101
Sacramento, CA 95827
Telephone: 916.369.7581

**Florida**
Central Florida Chapter
5333 West Dartmouth Avenue
Tampa, FL 33618
Telephone: 813.963.6461

Northern Florida
9143 Phillips Highway • Suite 130
Jacksonville, FL 32256
Telephone: 904.938.0721

South Florida Chapter
3225 Hollywood Boulevard • Suite 400
Hollywood, FL 33021
Telephone: 954.961.3234

Suncoast Chapter
13907 North Dale Mabry Highway • Suite 101
Tampa, FL 33618
Telephone: 813.963.0461

**Georgia**
Georgia Chapter
2625 Cumberland Parkway • Suite 205
Atlanta, GA 30359
Telephone: 404.438.6006

**Illinois**
Illinois Chapter
100 West Monroe • Suite 1610
Chicago, IL 60603
Telephone: 312.726.0005

**Indiana**
Indiana Chapter
921 East 80th Street • Suite 100
Indianapolis, IN 46240
Telephone: 317.726.2270

**Iowa**
Iowa Chapter
8035 University Boulevard • Suite A
Des Moines, IA 50325
Telephone: 515.270.6169 or 800.374.1074

**Kansas**
Kansas Chapter
555 N. Woodlawn, Building 1 • Suite 113
Wichita, KS 67208
Telephone: 316.867.2222

Mid-America Chapter
Cloverleaf Building No. 1
6811 West 63rd Street • Suite 2020
Shawnee Mission, KS 66202-4001
Telephone: 913.262.1515

**Kentucky**
Kentucky Chapter
710 West Main Street • Suite 201
Louisville KY 40202-2690
Telephone: 502.584.6490

**Louisiana**
Louisiana Chapter
3636 South 1-10 Service Road • Suite 304
Metairie, LA 70002
Telephone: 504.837.0045

**Maryland**
Maryland Chapter
Chester Building
6600 LaSalle Road • Suite 314
Baltimore, MD 21216-2011
Telephone: 410.825.2500

**Massachusetts**
Massachusetts Chapter
495 Old Connecticut Path • Suite 220
Framingham, MA 01701-4567
Telephone: 508.879.5083 or 800.688.6572

**Michigan**
Michigan Chapter
1421 East Twelve Mile Road • Building A
Madison Heights, MI 48071
Telephone: 248.582.2900

**Minnesota**
Minnesota Chapter
5217 Wayzata Boulevard • Suite 221
St. Louis Park, MN 55416
Telephone: 952.543.3309

**Mississippi**
Mississippi Chapter
405 Fontaine Place • Suite 103
Ridgeland, MS 39157
Telephone: 601.936.7447

**Missouri**
Gateway Chapter
77 West Port Plaza • Suite 101
St. Louis, MO 63146-3111
Telephone: 314.878.0780

**Nebraska**
Nebraska Chapter
2605 Farnam Street
Omaha, NE 68131
Telephone: 402.344.2242

**New Mexico**
New Mexico/El Paso Chapter
3150 Carlisle, N.E. • Suite 35
Albuquerque, NM 87110
Telephone: 505.830.6040

**New York**
Central New York Chapter
Learbury Centre
410 North Salina Street
Syracuse, NY 13203-1770
Telephone: 315.471.1030

Long Island Chapter
555 Broad Hollow Road
Melville, NY 11747
Telephone: 631.752.8500

New York City Chapter
475 Park Avenue South • 8th Floor
New York, NY 10016
Telephone: 212.448.9206

Upstate New York/Vermont Chapter
6 Automation Lane
Albany, NY 12205
Telephone: 518.438.3583

Westchester/Hudson Valley Chapter
1311 Mamaroneck Avenue • Suite 330
White Plains, NY 10605
Telephone: 914.949.0084

Western New York and Finger Lakes Chapter
4053 Maple Road
Amherst, NY 14226
Telephone: 716.854.2578

**North Carolina**
North Carolina Chapter
5950 Fairview Road • Suite 230
Charlotte, NC 28210
Telephone: 704.998.5012

**Ohio**
Central Ohio Chapter
2225 City Gate Drive • Suite E
Columbus, OH 43219
Telephone: 614.476.7194

Northern Ohio Chapter
902 Westpoint Parkway • Suite 300
Cleveland, OH 44145
Telephone: 440.612.2873

**Oregon**
Southern Nevada Chapter
6280 South Valley View Boulevard • Suite 112
Las Vegas, NV 89118
Telephone: 702.436.4220

Southern Nevada Chapter
3150 Carlisle, N.E. • Suite 35
Albuquerque, NM 87110
Telephone: 505.830.6040

New Mexico/El Paso Chapter
3150 Carlisle, N.E. • Suite 35
Albuquerque, NM 87110
Telephone: 505.830.6040

**Pennsylvania**
Central Pennsylvania Chapter
300 Research Parkway • Suite 100
Harrisburg, PA 17110
Telephone: 717.765.8220

Eastern Pennsylvania Chapter
3300 Meetinghouse Road • Suite 1
Gettysburg, PA 17325
Telephone: 717.765.8220

Western Pennsylvania and West Virginia Chapter
Two Gateway Center • 13 North
Pittsburgh, PA 15222
Telephone: 412.395.2873

**Rhode Island**
Rhode Island Chapter
1247 Lake Murray Boulevard
Irmo, SC 29063
Telephone: 803.749.4299

**South Carolina**
South Carolina Chapter
75 Stocktonnet Crossroad • Suite 206
Box 8099
Cramerton, NC 28020
Telephone: 704.943.8888

**Tennessee**
Tennessee Chapter
446 Metropolis Drive • Suite A-200
Nashville, TN 37211-3139
Telephone: 615.331.2980

**Texas**
North Texas Chapter
12850 Spurline Drive • Suite 220
Dallas, TX 75230
Telephone: 972.239.0999

South/West Texas Chapter
950 Isum Road • Suite 104
San Antonio, TX 78216
Telephone: 210.373.1775

Texas Gulf Coast Chapter
5005 Mitchelldale • Suite 115
Fax: 409.863.0037

**Virginia**
Virginia Chapter
5111 Staples Mill Road • Suite 105
Richmond, VA 23228
Telephone: 804.827.0400

**Washington**
Washington/Alaska Chapter
530 Dexter Avenue North • Suite 300
Seattle, WA 98109
Telephone: 206.628.0778

**Wisconsin**
Wisconsin Chapter
4125 N. 124th Street • Unit A
Brookfield, WI 53005
Telephone: 262.790.4701
The loss of their daughter created in the Ranadies the need to find a cure.

“We lost our beautiful daughter to CML. Nothing can change that. But there is solace in knowing that today there is a targeted therapy for this cancer that is keeping many people alive and well — and that by funding researchers through the Society, we are helping find cures.”
The Society is a nonprofit organization that relies on the generosity of individual and corporate contributions to advance its mission. Call our Information Resource Center toll free at 800.955.4572 or visit www.LLS.org

The Leukemia & Lymphoma Society
Fighting Blood-Related Cancers

1311 Mamaroneck Avenue
White Plains, New York 10605
Telephone 914.949.5213
Facsimile 914.949.6691

www.LLS.org